Skip to main content

Table 1 Basic characteristics of included studies

From: Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis

Authors

Year

Study period

Country

Sample size

MFP

(months)

Study type

Histology type

Cut-off

Endpoint

Source of HR

Nos

Aoki et al. [17]

2001

1990–1999

Japan

127

37.1

Retro

ADA

0.5

OS

E

7

Higashi et al. [18]

2009

1997–2005

Japan

87

18

Retro

ADA

0.5

DFS

E

7

Koike et al. [19]

2012

1992–2009

Japan

223

70

Retro

NSCLC

0.75

OS

R

8

Kishimoto et al. [20]

2014

2006–2010

Japan

169

42

Retro

NSCLC

C

DFS

R

8

Nakamura et al. [22]

2015

2005–2011

Japan

113

46

Retro

ADA

0.5

OS/DFS

R

8

Shimada et al. [23]

2015

2004–2010

Japan

67

58.9

Retro

NSSLC

0.5

OS/RFS

R

8

Cho et al. [21]

2015

2001–2010

Korea

97

44.7

Retro

ADA

0.25

OS/RFS

E

8

Tsurugai et al. [24]

2016

2005–2014

Japan

155

34.7

Retro

NSCLC

0.5

OS/DFS

R

8

Suzuki et al. [25]

2017

2003–2007

Japan

392

84

Retro

ADA

0.5

OS/RFS

E

7

Tsunezuka et al. [26]

2017

2008–2012

Japan

62

55.1

Retro

NSCLC

0.5

OS/RFS

R

7

Huang et al. [27]

2018

2004–2013

China

789

87

Retro

ADA

0.75

OS/DFS

E

7

Ye et al. [28]

2018

2008–2014

China

736

38

Retro

ADA

C

RFS

R

7

Kamigaichi et al. [29]

2019

2007–2016

Japan

166

49.3

Retro

NSCLC

0.85

OS/RFS

E

7

Kim et al. [13]

2019

2009–2015

Korea

691

39

Retro

ADA

0.5

DFS

R

7

Ye et al. [6]

2019

2008–2014

China

329

42.2

Retro

ADA

0.5

OS

R

8

Kuroda et al. [31]

2020

2006–2010

Japan

260

83.8

Retro

NSCLC

0.5

OS/DFS

R

7

Kabalak et al. [30]

2020

2013–2016

Turkey

156

40

Retro

ADA

0.5

OS/PFS

E

8

RYOJI IWAMOTO et al. [33]

2021

2000–2009

Japan

73

77

Retro

ADA

0.8

OS

R

7

Takamori et al. [37]

2021

2006–2014

Japan

85

87.6

Retro

NSCLC

0.5

OS

E

7

Sun et al. [36]

2021

2014.01–2014.12

China

257

76

Retro

NSCLC

C

OS/RFS

R

7

Zhong et al. [39]

2021

2011–2012

China

620

72.4

Retro

ADA

C

OS/RFS

R

7

Ji et al. [34]

2021

2014–2015

China

190

51

Retro

ADA

0.5

PFS

R

7

Lin et al. [35]

2021

2013–2015

China

372

55

Retro

ADA

0.5

RFS

R

7

Xi et al. [12]

2021

2011–2016

China

862

47

Retro

ADA

C

RFS

R

7

Chiang et al. [32]

2021

2011–2017

China

1002

43.2

Retro

ADA

0.5

DFS

R

8

Tsai et al. [38]

2021

2003–2015

China

149

74

Retro

ADA

0.5

OS/DFS

R

8

Hattori et al. [40]

2022

2008–2017

Japan

603

54

Retro

ADA

C

OS

R

8

Nakao et al. [41]

2022

2010–2017

Japan

1014

61

Retro

ADA

C

OS

R

8

Zhai et al. [42]

2022

2008–2018

China

501

64.8

Retro

ADA

0.75

OS/DFS

R

8

  1. MFP median follow-up time, HR hazard ratio, NOS Newcastle–Ottawa scale, NSCLC non-small cell lung cancer, Retro retrospective, ADA adenocarcinoma, C continuous, OS overall survival, DFS disease-free survival; RFS, recurrence-free survival, PFS progression-free survival, E estimated, R reported, NA not available